INTERCEPT PHARMACEUTICALS INC 4
4 · INTERCEPT PHARMACEUTICALS INC · Filed Feb 3, 2015
Insider Transaction Report
Form 4
Regan Daniel Paul
Chief Commerical Officer
Transactions
- Sale
Common Stock
2015-01-30$208.08/sh−200$41,616→ 1,264 total - Exercise/Conversion
Common Stock
2015-01-30$37.69/sh+9,847$371,133→ 11,111 total - Sale
Common Stock
2015-01-30$200.07/sh−6,847$1,369,859→ 4,264 total - Sale
Common Stock
2015-01-30$201.50/sh−1,207$243,213→ 3,057 total - Exercise/Conversion
Option to Purchase Common Stock
2015-01-30−9,847→ 92,028 totalExercise: $37.69Exp: 2023-03-04→ Common Stock (9,847 underlying) - Sale
Common Stock
2015-01-30$202.49/sh−793$160,577→ 2,264 total - Sale
Common Stock
2015-01-30$205.87/sh−800$164,698→ 1,464 total
Footnotes (6)
- [F1]The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 14, 2014.
- [F2]The remaining shares underlying this option vest on a pro rata monthly basis through March 4, 2017, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan.
- [F3]This transaction was executed in multiple trades at prices ranging from $200.0000 to $200.8100. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This transaction was executed in multiple trades at prices ranging from $201.0100 to $202.0000. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F5]This transaction was executed in multiple trades at prices ranging from $202.0100 to $203.0000. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F6]This transaction was executed in multiple trades at prices ranging from $205.5000 to $206.2450. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.